OSLO, Norway, Dec. 7, 2020 /PRNewswire/ -- Photocure
ASA (OSE:PHO) today announced new data and analyses presented at
the 21st Annual Meeting of the Society of Urologic
Oncology (SUO). Presentations discussed the use of Blue Light
Cystoscopy (BLC™) with Cysview®, in particular the
positive impact on patient outcomes in the surveillance setting
without a significant impact on the cost of care, as well as the
benefits of identifying early recurrences in high-risk NMIBC
patients undergoing BCG treatment.
The SUO meeting, held virtually this year, is led by
internationally renowned urologic oncologists, medical oncologists,
and scientists and attracts the interest of experts from all over
the world.
"The use of BLC with Cysview continues to inspire the
scientific community as much as ever for improving the care of
patients diagnosed with bladder cancer. These new abstracts
highlight the role of the procedure throughout patient care,
especially focusing on the impact on patient management when used
in surveillance. The Budget Impact Model supports the favorable
cost-benefit of blue light procedures including in the office
setting, while reaffirming its superiority in detection of
non-muscle-invasive bladder cancer compared to white light alone.
Both healthcare systems and patients clearly benefit from this
standard of care procedure", said Dan
Schneider, President and CEO of Photocure.
BLC with Cysview abstracts and posters have been prominently
featured at the SUO meeting, including:
- Budget Impact of Blue Light Cystoscopy in The Surveillance
Setting
Stephen B. Williams, et al. The
University of Texas Medical Branch
The Budget Impact Model was developed based on standard
protocols for the treatment and surveillance of NMIBC. Inputs were
based on a simulated facility with 50 newly diagnosed bladder
cancer patients. Blue Light Cystoscopy (BLC) with Cysview was
utilized for all surveillance cystoscopies. In the office setting,
the additional use of flexible BLC for surveillance did not
substantially impact cost and resulted in the identification of 9
recurrences over the course of two years that would otherwise be
missed.
Link to the abstract
- Using BLC at the 3-Month Post-BCG Cystoscopy, Impact on
Cancer Diagnosis, and Implications for Clinical Trial Design and
Definition of BCG Response
Meera R. Chappidi, et al.
University of California San
Francisco
"We initiated this study because the utility of blue light
cystoscopy (BLC) for surveillance in patients receiving BCG
treatments is really not well understood. Thus, no recommendations
exist in current guidelines. Beyond the obvious benefit of
detecting recurrences that would otherwise be missed, we think that
identifying early recurrences in patients receiving BCG can result
in them being enrolled into clinical trials for BCG unresponsive
disease in a timely manner", said Dr. Max Kates, Assistant Professor of Urology and
Oncology, Co-Director, Bladder Cancer Multidisplinary
Clinic, The James Buchanan Brady Urologic Institute of
Johns Hopkins School of Medicine.
Based on findings from the Blue Light Cystoscopy (BLC) with
Cysview Multi-institutional Registry, BLC-alone identified patients
with recurrences after recent BCG treatment that would have been
missed with White-light Cystoscopy (WLC) alone. This could be
interpreted as WLC-alone incorrectly assessing inflated complete
response rates in comparison to the more accurately measured
results when BLC is added for surveillance (60% vs 55.3%). The
implications of misidentified complete responses lead to inflated
efficacy results, incorrect statistical findings and misguided
conclusions. Future research is needed to clarify how BLC should be
used for both entry into clinical trials and for surveillance while
on trials.
Link to the abstract
Note to editors:
All trademarks mentioned in this release are protected by law
and are registered trademarks of Photocure ASA
This press release may contain product details and information
which are not valid, or a product is not accessible, in your
country. Please be aware that Photocure does not take any
responsibility for accessing such information which may not comply
with any legal process, regulation, registration or usage in the
country of your origin.
About Bladder Cancer
Bladder cancer ranks as the sixth most common cancer worldwide
with 1 650 000 prevalent cases (5-year prevalence rate),
550 000 new cases and almost 200 000 deaths annually in
2018.1
Approx. 75% of all bladder cancer cases occur in
men.1 It has a high recurrence rate with an average of
61% in year one and 78% over five years.2 Bladder cancer
has the highest lifetime treatment costs per patient of all
cancers.3
Bladder cancer is a costly, potentially progressive disease for
which patients have to undergo multiple cystoscopies due to the
high risk of recurrence. There is an urgent need to improve both
the diagnosis and the management of bladder cancer for the benefit
of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive
bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC),
depending on the depth of invasion in the bladder wall. NMIBC
remains in the inner layer of cells lining the bladder. These
cancers are the most common (75%) of all BC cases and include the
subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the
cancer has grown into deeper layers of the bladder wall. These
cancers, including subtypes T2, T3 and T4, are more likely to
spread and are harder to treat.4
1 Globocan. Incidence/mortality by population.
Available at
http://globocan.iarc.fr/Pages/bar_pop_sel.aspx
2 Babjuk M, et al. Eur Urol. 2019; 76(5):
639-6573 Sievert KD et al. World J Urol
2009;27:295-3004 Bladder Cancer. American Cancer
Society. https://www.cancer.org/cancer/bladder-cancer.html
About
Hexvix®/Cysview® (hexaminolevulinate
HCl)
Hexvix®/Cysview® is a drug that
preferentially accumulates in cancer cells in the bladder making
them glow bright pink during Blue Light Cystoscopy
(BLCTM). BLC™ with Hexvix®
/Cysview® improves the detection of tumors and leads to
more complete resection, fewer residual tumors and better
management decisions.
Cysview® is the tradename in the U.S. and
Canada, Hexvix® is the
tradename in all other markets. Photocure is commercializing
Cysview® /Hexvix® directly in the U.S. and
the Nordic region and has strategic partnerships for the
commercialization of Hexvix®/Cysview® in
Europe, Canada, Australia and New
Zealand. Please refer to https://bit.ly/2wzqSQQ for
further information on our commercial partners.
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative
solutions to improve the lives of bladder cancer patients. Our
unique technology, making cancer cells glow bright pink, has led to
better health outcomes for patients worldwide. Photocure is
headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information,
please visit us at www.photocure.com , www.hexvix.com ,
www.cysview.com
CONTACT:
For further information, please contact:
Photocure
Dan Schneider
President and CEO
Tel: +1-609 759-6515
Email: ds@photocure.com
Erik Dahl
CFO
Tel: +47 45055000
Email: ed@photocure.com
Media and IR enquiries:
Geir BjørloCorporate Communications (Norway)Tel: +47 91540000Email:
geir.bjorlo@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/photocure/r/new-abstracts-on-the-use-of-blue-light-cystoscopy-with-cysview-presented-at-suo,c3249830
The following files are available for download:
https://mb.cision.com/Main/17498/3249830/1344762.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/new-abstracts-on-the-use-of-blue-light-cystoscopy-with-cysview-presented-at-suo-301187056.html
SOURCE Photocure